GSK – GlaxoSmithKline plc
GSK plcGSK
$36.53Name : GSK plc
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $74,195,345,408.00
EPSttm : 1.61
GSK plc
$36.53
6.36%$2.48Float Short %
0.86
Margin Of Safety %
22
Put/Call OI Ratio
0.5
EPS Next Q Diff
0.46
EPS Last/This Y
EPS This/Next Y
0.4
Price
39.01
Target Price
42.12
Analyst Recom
2.79
Performance Q
15.35
Relative Volume
2.22
Beta
0.52
Ticker: GSK
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | GSK | 38.81 | 0.47 | 0.53 | 108456 |
| 2025-03-06 | GSK | 39.31 | 0.46 | 0.69 | 108514 |
| 2025-03-07 | GSK | 40.04 | 0.47 | 0.51 | 109327 |
| 2025-03-10 | GSK | 40.31 | 0.46 | 2.18 | 110661 |
| 2025-03-11 | GSK | 39.51 | 0.56 | 1.72 | 121716 |
| 2025-03-12 | GSK | 38.88 | 0.55 | 0.59 | 124103 |
| 2025-03-13 | GSK | 39.25 | 0.55 | 5.07 | 124970 |
| 2025-03-14 | GSK | 39.49 | 0.61 | 0.24 | 131494 |
| 2025-03-17 | GSK | 40.27 | 0.64 | 0.08 | 128530 |
| 2025-03-18 | GSK | 40.4 | 0.56 | 0.26 | 130453 |
| 2025-03-19 | GSK | 39.55 | 0.56 | 2.19 | 131005 |
| 2025-03-20 | GSK | 39.44 | 0.56 | 8.23 | 132053 |
| 2025-03-21 | GSK | 39.26 | 0.63 | 6.29 | 137887 |
| 2025-03-24 | GSK | 38.58 | 0.46 | 1.82 | 110292 |
| 2025-03-25 | GSK | 38.58 | 0.47 | 2.04 | 112459 |
| 2025-03-26 | GSK | 38.31 | 0.48 | 1.05 | 113820 |
| 2025-03-27 | GSK | 38.51 | 0.50 | 8.17 | 115572 |
| 2025-03-28 | GSK | 38.75 | 0.53 | 8.61 | 118039 |
| 2025-03-31 | GSK | 38.77 | 0.53 | 1.53 | 116575 |
| 2025-04-01 | GSK | 37.88 | 0.52 | 0.93 | 116938 |
| 2025-04-02 | GSK | 37.63 | 0.53 | 0.49 | 121767 |
| 2025-04-03 | GSK | 38.98 | 0.50 | 0.16 | 128969 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | GSK | 38.81 | -5.9 | 6894.8 | 4.26 |
| 2025-03-06 | GSK | 39.31 | -5.9 | 7276.2 | 4.26 |
| 2025-03-07 | GSK | 40.03 | -5.9 | 7133.7 | 4.26 |
| 2025-03-10 | GSK | 40.32 | -5.9 | 6986.5 | 4.26 |
| 2025-03-11 | GSK | 39.51 | -5.9 | 6701.2 | 4.26 |
| 2025-03-12 | GSK | 38.88 | -5.9 | 6919.3 | 4.26 |
| 2025-03-13 | GSK | 39.25 | -5.9 | 7294.9 | 4.26 |
| 2025-03-14 | GSK | 39.49 | -5.9 | 7247.6 | 4.26 |
| 2025-03-17 | GSK | 40.25 | -5.9 | 7369.7 | 4.26 |
| 2025-03-18 | GSK | 40.37 | -5.9 | 7117.8 | 4.26 |
| 2025-03-19 | GSK | 39.55 | -5.9 | 6820.4 | 4.26 |
| 2025-03-20 | GSK | 39.41 | -5.9 | 7128.8 | 4.26 |
| 2025-03-21 | GSK | 39.26 | -5.9 | 7139.4 | 4.26 |
| 2025-03-24 | GSK | 38.57 | -5.9 | 7047.4 | 4.26 |
| 2025-03-25 | GSK | 38.58 | -5.9 | 7064.6 | 4.26 |
| 2025-03-26 | GSK | 38.31 | -5.9 | 7155.3 | 4.26 |
| 2025-03-27 | GSK | 38.52 | -5.9 | 7125.5 | 4.26 |
| 2025-03-28 | GSK | 38.74 | -5.9 | 7218.7 | 4.26 |
| 2025-03-31 | GSK | 38.76 | -5.9 | 7085.5 | 4.26 |
| 2025-04-01 | GSK | 37.87 | -5.9 | 8221.1 | 4.26 |
| 2025-04-02 | GSK | 37.64 | -5.9 | 8140.6 | 4.26 |
| 2025-04-03 | GSK | 39.01 | -5.9 | 8845.8 | 4.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | GSK | 0 | 0.35 | 0.69 |
| 2025-03-06 | GSK | 0 | 0.35 | 0.69 |
| 2025-03-07 | GSK | 0 | 0.35 | 0.69 |
| 2025-03-10 | GSK | 0 | 0.32 | 0.69 |
| 2025-03-11 | GSK | 0 | 0.32 | 0.69 |
| 2025-03-12 | GSK | 0 | 0.32 | 0.91 |
| 2025-03-13 | GSK | 0 | 0.32 | 0.91 |
| 2025-03-14 | GSK | 0 | 0.32 | 0.91 |
| 2025-03-17 | GSK | 0 | -2.10 | 0.91 |
| 2025-03-18 | GSK | 0 | -2.10 | 0.91 |
| 2025-03-19 | GSK | 0 | -2.10 | 0.91 |
| 2025-03-20 | GSK | 0 | -2.10 | 0.91 |
| 2025-03-21 | GSK | 0 | -2.10 | 0.91 |
| 2025-03-24 | GSK | 0 | -3.05 | 0.91 |
| 2025-03-25 | GSK | 0 | -3.05 | 0.91 |
| 2025-03-26 | GSK | 0 | -3.05 | 0.86 |
| 2025-03-27 | GSK | 0 | -3.05 | 0.86 |
| 2025-03-28 | GSK | 0 | -3.05 | 0.86 |
| 2025-03-31 | GSK | 0 | -3.20 | 0.86 |
| 2025-04-01 | GSK | 0 | -3.20 | 0.86 |
| 2025-04-02 | GSK | 0 | -3.20 | 0.86 |
| 2025-04-03 | GSK | 0 | -3.20 | 0.86 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.59
Avg. EPS Est. Current Quarter
1.01
Avg. EPS Est. Next Quarter
1.05
Insider Transactions
Institutional Transactions
-3.2
Beta
0.52
Average Sales Estimate Current Quarter
7524
Average Sales Estimate Next Quarter
8057
Fair Value
47.64
Quality Score
84
Growth Score
69
Sentiment Score
65
Actual DrawDown %
19.2
Max Drawdown 5-Year %
-39.3
Target Price
42.12
P/E
24.65
Forward P/E
8.2
PEG
2.92
P/S
1.98
P/B
4.65
P/Free Cash Flow
13.11
EPS
1.58
Average EPS Est. Cur. Y
4.26
EPS Next Y. (Est.)
4.67
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
8.13
Relative Volume
2.22
Return on Equity vs Sector %
-1
Return on Equity vs Industry %
-8.2
EPS 1 7Days Diff
EPS 1 30Days Diff
0.17
EBIT Estimation
8845.8
GSK plcSector: Healthcare
Industry: Drug Manufacturers - General
Employees: 68629
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.
stock quote shares GSK – GlaxoSmithKline plc Stock Price stock today
news today GSK – GlaxoSmithKline plc stock forecast ,stock prediction 2023 2024 2025
marketwatch GSK – GlaxoSmithKline plc yahoo finance google finance
stock history GSK – GlaxoSmithKline plc invest stock market
stock prices GSK premarket after hours
ticker GSK fair value insiders trading